Cisplatin-based chemotherapy for advanced or recurrent endometrial cancer - a review of 36 cases

Thirty-six patients with advanced or recurrent endometrial cancer having had no previous chemotherapy were treated with cisplatin-based chemotherapy. The overall response rate was 38.9%. The mean time to response and the mean duration of response were 9.6 weeks and 16.9 months, respectively. There was no significant difference in response and survival probability between persistent disease and recurrent disease. Size of tumor had a marked influence on response, while age, history of previous irradiation and histologic grade of adenocarcinoma did not affect the response rate. Survival probability by response clearly demonstrated that only complete response exhibited a large impact on survival.